
Fasoracetam is a newer racetam nootropic originally developed by Nippon Shinyaku in the 1990s for the treatment of vascular dementia. While it failed to show sufficient efficacy in Phase 3 trials for dementia, it was later licensed by Aevi Technologies (now Aevi Genomic Medicine) for the treatment of ADHD in adolescents with mutations in the mGluR gene network. Fasoracetam is unique among racetams for its potent upregulation of GABA-B receptors and modulation of metabotropic glutamate receptors (mGluR), making it of particular interest for anxiety, phenibut/GHB withdrawal support, and ADHD. It has gained popularity in the nootropics community for its anxiolytic properties and its reported ability to restore GABA-B receptor sensitivity after downregulation from GABAergic drugs.
Harm Reduction
Standard nootropic dosing is 20-100 mg sublingually or orally, once to twice daily. Sublingual administration is preferred by many users as it bypasses first-pass metabolism and produces faster onset....
Read full harm reduction guide